5Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165). of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem, 1996, 271: 7788-7795.
6Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Springer Harbor Lab Press, 1989.880-897.
7Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995, 1: 27-31.
8Jinno K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol, 1998, 33: 376-382.
9Oku T, Tjuvajev JG, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res, 1998, 58: 4185-4192.
10Ferrara N, Henzel WJ. Pituitary follicular cells secrete anovel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commum, 1989, 161(2): 851-858.
6Schneider R, Higgins M J, Kieninger D, et al. The Human ribonu- clese angiogenin inhibitor is encoded by a gene mapped to chromo- some 11 p15.5, within 90kb of the H-RAS protooncogene[ J]. Cy- togenet Cell Gene, 1992,59(4) :264-267.
7Lee Fs, Shapiro R, Vallee BL. Tight-Binding inhibition of angio- genin and ribonuclease A by placental fibonuclease inhibitor [ J ].Biochemistry, 1988,28( 1 ) :225-227.
8Lee Fs, Auld DS, Vallee BL. Trptophan fluorescence as a probe of placental ribonuclease inhibitor binding to angiogenin [ J ]. Bio- chemistry, 1989,28( 1 ) :219-210.
9Cui XY, Fu PF, Pan DN, et al. The antioxidant effects of ribonu- clease inhibitor[J]. Free Radie Res, 2003,37(10) :1079-1085.
